Gregory T. Golm

3.1k total citations
52 papers, 2.5k citations indexed

About

Gregory T. Golm is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Gregory T. Golm has authored 52 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Endocrinology, Diabetes and Metabolism, 25 papers in Molecular Biology and 15 papers in Surgery. Recurrent topics in Gregory T. Golm's work include Diabetes Treatment and Management (40 papers), Metabolism, Diabetes, and Cancer (25 papers) and Diabetes Management and Research (20 papers). Gregory T. Golm is often cited by papers focused on Diabetes Treatment and Management (40 papers), Metabolism, Diabetes, and Cancer (25 papers) and Diabetes Management and Research (20 papers). Gregory T. Golm collaborates with scholars based in United States, France and China. Gregory T. Golm's co-authors include Keith D. Kaufman, Samuel S. Engel, Barry J. Goldstein, Jeremy Johnson, Debora Williams‐Herman, Brett Lauring, Steven G. Terra, Susan Huyck, James P. Mancuso and Michael J. Davies and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of the American College of Cardiology and Diabetes Care.

In The Last Decade

Gregory T. Golm

50 papers receiving 2.4k citations

Peers

Countries citing papers authored by Gregory T. Golm

Since Specialization

Citations

This map shows the geographic impact of Gregory T. Golm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory T. Golm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory T. Golm more than expected).

Fields of papers citing papers by Gregory T. Golm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory T. Golm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory T. Golm. The network helps show where Gregory T. Golm may publish in the future.

Co-authorship network of co-authors of Gregory T. Golm

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory T. Golm. A scholar is included among the top collaborators of Gregory T. Golm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory T. Golm. Gregory T. Golm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prior Effective Sample Size When Borrowing on the Treatment Effect Scale 2025 ·Statistics in Medicine ·(unknown), Keaven M. Anderson, Zachary Zimmer, Gregory T. Golm, Aditi Sapre, Joseph G. Ibrahim	0
2	Evaluation of Responder Thresholds for PAH-SYMPACT Domain Scores in Patients With Sotatercept Treatment in the STELLAR Study 2024 ·(unknown), Janethe de Oliveira Pena, F. Wang, Gregory T. Golm, Brian Miller, Dena Rosen Ramey	1
3	Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: A randomized, open‐label clinical trial 2018 ·Diabetes Obesity and Metabolism ·Priscilla Hollander, (unknown), Raymond L. H. Lam, Gregory T. Golm, Roy Eldor, Michael F. Crutchlow, (unknown), Marc Rendell, Philip Home, Baptist Gallwitz, Julio Rosenstock	10
4	Efficacy and safety of MK‐1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open‐label clinical trial 2018 ·Diabetes Obesity and Metabolism ·Philip Home, Raymond L. H. Lam, (unknown), Gregory T. Golm, Roy Eldor, Michael F. Crutchlow, (unknown), Julio Rosenstock, Priscilla Hollander, Baptist Gallwitz	5
5	DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV) 2018 ·Journal of the American College of Cardiology ·Christopher P. Cannon, Darren K. McGuire, Richard E. Pratley, Samuel Dagogo‐Jack, James P. Mancuso, Susan Huyck, B Charbonnel, Weichung Shih, Silvina Gallo, Urszula Masiukiewicz, Gregory T. Golm, Francesco Cosentino, Brett Lauring, Steven G. Terra	55
6	Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study 2018 ·Diabetes Therapy ·Sam S. Miller, (unknown), Hao Zhou, Susan Huyck, Jeremy Johnson, Gregory T. Golm, Steven G. Terra, James P. Mancuso, Samuel S. Engel, Brett Lauring	70
7	Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study 2017 ·Diabetes Therapy ·Priscilla Hollander, Jie Liu, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory T. Golm, Susan Huyck, Steven G. Terra, James P. Mancuso, Samuel S. Engel, Brett Lauring	88
8	Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial 2015 ·Drugs & Aging ·(unknown), Yue Shentu, (unknown), Gregory T. Golm, Christine McCrary Sisk, Samuel S. Engel, R. Ravi Shankar	24
9	A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine 2015 ·Diabetes Therapy ·Chantal Mathieu, R. Ravi Shankar, Daniel Lorber, Guillermo E. Umpierrez, Fan Wu, Lei Xu, Gregory T. Golm, Melanie Latham, Keith D. Kaufman, Samuel S. Engel	32
10	Safety of Sitagliptin in Elderly Patients with Type 2 Diabetes: A Pooled Analysis of 25 Clinical Studies 2014 ·Drugs & Aging ·Elizabeth Round, Samuel S. Engel, Gregory T. Golm, Michael J. Davies, Keith D. Kaufman, Barry J. Goldstein	32
11	Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies 2013 ·Diabetes Therapy ·Samuel S. Engel, Elizabeth Round, Gregory T. Golm, Keith D. Kaufman, Barry J. Goldstein	105
12	Assessment of AACE/ACE Recommendations for Initial Dual Antihyperglycemic Therapy Using the Fixed-Dose Combination of Sitagliptin and Metformin Versus Metformin 2013 ·Endocrine Practice ·Samuel S. Engel, Thomas Seck, Gregory T. Golm, Alan G. Meehan, Keith D. Kaufman, Barry J. Goldstein	9
13	Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo‐controlled 54‐week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)* 2012 ·Journal of Diabetes ·Adrian S. Dobs, Barry J. Goldstein, Pablo Aschner, Edward S. Horton, Guillermo E. Umpierrez, (unknown), Julie Hill, Yu Chen, Gregory T. Golm, Ronald B. Langdon, Debora Williams‐Herman, Keith D. Kaufman, John M. Amatruda, Juan Camilo Arjona Ferreira	38
14	Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes 2012 ·Journal of Diabetes and its Complications ·Vivian Fonseca, Bart Staels, (unknown), Yue Shentu, Gregory T. Golm, Amy O. Johnson‐Levonas, Keith D. Kaufman, Barry J. Goldstein, Helmut O. Steinberg	45
15	Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide 2011 ·Diabetes Research and Clinical Practice ·Thomas Seck, Samuel S. Engel, Debora Williams‐Herman, Christine McCrary Sisk, Gregory T. Golm, Hongwei Wang, Keith D. Kaufman, Barry J. Goldstein	20
16	Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes 2011 ·International Journal of Clinical Practice ·Kun‐Ho Yoon, (unknown), R. Teng, Gregory T. Golm, (unknown), (unknown), Debora Williams‐Herman, Keith D. Kaufman, John M. Amatruda, H. Steinberg	47
17	Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis 2010 ·International Journal of Clinical Practice ·Samuel S. Engel, Debora Williams‐Herman, Gregory T. Golm, (unknown), S. V. Machotka, Keith D. Kaufman, B. J. Goldstein	111
18	Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes 2010 ·BMC Endocrine Disorders ·Debora Williams‐Herman, Samuel S. Engel, Elizabeth Round, Jeremy Johnson, Gregory T. Golm, Hua Guo, Bret J. Musser, Michael J. Davies, Keith D. Kaufman, Barry J. Goldstein	215
19	Semiparametric Methods for Multiple Exposure Mismeasurement and a Bivariate Outcome in HIV Vaccine Trials 1999 ·Biometrics ·Gregory T. Golm, M. Elizabeth Halloran, Ira M. Longini	11
20	Semi-parametric models for mismeasured exposure information in vaccine trials 1998 ·Statistics in Medicine ·Gregory T. Golm, M. Elizabeth Halloran, Ira M. Longini	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact